tradingkey.logo

Lifecore Biomedical Inc

LFCR
View Detailed Chart

7.930USD

+0.230+2.99%
Close 09/18, 16:00ETQuotes delayed by 15 min
293.62MMarket Cap
LossP/E TTM

Lifecore Biomedical Inc

7.930

+0.230+2.99%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.99%

5 Days

+2.06%

1 Month

+7.16%

6 Months

+20.70%

Year to Date

+6.73%

1 Year

+52.50%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
76 / 175
Overall Ranking
205 / 4723
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.000
Target Price
+27.23%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.79% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 44.36M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -6.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 27.35M shares, decreasing 9.34% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.61M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Ticker SymbolLFCR
CompanyLifecore Biomedical Inc
CEOMr. Paul Josephs
Websitehttps://www.lifecore.com/
KeyAI